Bennett Daniel Mark, Currie James, Fernie Gordon, Perrin Jennifer S, Reid Ian C
From the Division of Applied Medicine (Psychiatry), University of Aberdeen, Aberdeen, Scotland, UK.
J ECT. 2016 Dec;32(4):243-250. doi: 10.1097/YCT.0000000000000325.
The study aimed to explore cognitive outcomes after electroconvulsive therapy (ECT) depending on which version of common single nucleotide polymorphisms the patient expressed for brain-derived neurotrophic factor (BDNF) and catechol-O-methyltransferase (COMT).
A total of 87 patients from the clinical ECT service in Aberdeen, Scotland, were included in the study. Cognitive function testing (using Spatial Recognition Memory task from the Cambridge Neuropsychological Test Automated Battery and Mini-Mental State Examination) and mood ratings (Montgomery-Åsberg Depression Rating Scale) were performed before ECT, after 4 treatments, at the end of ECT and 1 and 3 months after the end of treatment. These scores were compared depending on BDNF and COMT variant at each time point using the Student t test and using a time series generalized least squares random effects model.
No differences were found between the val and met versions of the BDNF or COMT polymorphism in either cognitive or mood outcomes at any time point during ECT treatment or up to 3 months of follow-up.
This study did not detect significant differences in cognitive or mood outcomes between patients who have the val66val or met versions of the BDNF polymorphism. Our results suggest that these polymorphisms will not be helpful in clinical practice for predicting cognitive outcomes after ECT.
本研究旨在探讨电休克治疗（ECT）后的认知结果，具体取决于患者所表达的脑源性神经营养因子（BDNF）和儿茶酚-O-甲基转移酶（COMT）常见单核苷酸多态性的版本。
来自苏格兰阿伯丁临床ECT服务的87名患者被纳入研究。在ECT治疗前、4次治疗后、ECT结束时以及治疗结束后1个月和3个月进行认知功能测试（使用剑桥神经心理测试自动成套测验中的空间识别记忆任务和简易精神状态检查表）和情绪评分（蒙哥马利-阿斯伯格抑郁评定量表）。使用学生t检验，并采用时间序列广义最小二乘随机效应模型，在每个时间点根据BDNF和COMT变体比较这些分数。
在ECT治疗期间或长达3个月的随访中，BDNF或COMT多态性的val和met版本在任何时间点的认知或情绪结果方面均未发现差异。
本研究未检测到BDNF多态性为val66val或met版本的患者在认知或情绪结果上的显著差异。我们的结果表明，这些多态性在临床实践中对预测ECT后的认知结果并无帮助。
